Roche Diagnostics has received US FDA 510K clearance for the Accu-Chek Aviva metre, its newest blood glucose meter for the management of diabetes. The metre will be available for consumers in the US later this year.

"The new Accu-Chek Aviva meter has a strong combination of features paired with the dependability and ease of use that our customers have come to expect from Accu-Chek products," said Heino von Prondzynski, CEO, Division Roche Diagnostics and Member of Roche's Corporate Executive Committee. "The Accu-Chek Aviva meter offers people with diabetes a meter that makes testing simple and convenient, and underscores our commitment of creating solutions for easier diabetes management," he added.

These tools include the blood glucose monitoring portfolio of Accu-Chek Compact, Accu-Chek Advantage, Accu-Chek Active and Accu-Chek Complete meters, as well as the Accu-Chek MultiClix lancet device and Accu-Chek SoftClix lancet device, which helps minimize testing pain. In addition, Accu-Chek diabetes management software also is available for convenient data entry and storage, Roche said in a release.